Singapore’s Biolidics Limited is betting big on its COVID-19 rapid test kits after clearing regulatory hurdles from the health authorities in Singapore, the Philippines and the European Union.
The medtech company, which specializes in cancer treatment equipment and applications, has created a test kit that detects antibodies directed against the coronavirus that’s sweeping the world. Biolidics says the tests have an accuracy rate of 95% based on its clinical trial of 570 samples.
